NAGE · Niagen Bioscience, Inc. · Webcasts, Transcripts & Audio
$1.87
-0.08 (-3.87%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$153.64M
Shares
79.20M
Volume · Nov 19
188.29K
Avg daily vol (3M)
511.23K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Niagen Bioscience, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Niagen Bioscience, Inc. (NAGE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-10
Niagen Bioscience, Inc. (NAGE) December 10, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-19
Niagen Bioscience, Inc. (NAGE) November 19, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Niagen Bioscience, Inc. (NAGE) November 18, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-12
Niagen Bioscience, Inc. (NAGE) November 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript
Positive tone
NB4168 rare-disease development
China and Asian market expansion
Skincare expansion
Revenue
$27.19M
▼ 20% YoY Diluted EPS
$-0.01
▼ 120% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-11
Niagen Bioscience, Inc. (NAGE) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript
Positive tone
NanoCloud (water-soluble Niagen)
FDA lawsuit / motion to dismiss
NB4168 / pharmaceutical development
Revenue
$29.79M
▼ 4.3% YoY Diluted EPS
$0.01
▼ 75% YoY Gross margin
64.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Confident tone
Revenue and financial performance
Retail distribution strategy
Niagen Plus at-home injection launch
Revenue
$31.47M
▲ 3.3% YoY Diluted EPS
$0.07
▲ 16.7% YoY Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Confident tone
Financial Performance and 2026 Guidance
FDA Litigation and NMN Regulation
Competition and Market Growth
Revenue
$33.84M*
▲ 16.2% YoY Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Confident tone
Niagen Plus / Clinic & Injection Expansion
FDA Decision on NMN / Competitive Landscape
Revenue Growth & Financial Performance
Revenue
$33.99M
▲ 32.9% YoY Diluted EPS
$0.05
▲ 150% YoY Gross margin
64.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Niagen Bioscience, Inc. (NAGE) Q2 2025 Earnings Call Transcript
Confident tone
Parkinson's Drug Pathway
Revenue Growth
Niagen Plus / Clinic Channel
Revenue
$31.12M
▲ 36.8% YoY Diluted EPS
$0.04
Gross margin
65.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Niagen Bioscience, Inc. (NAGE) Q1 2025 Earnings Call Transcript
Confident tone
Niagen Plus (IV and injectables)
E-commerce / Tru Niagen
Pharmaceutical pipeline / clinical trials
Revenue
$30.48M
▲ 37.6% YoY Diluted EPS
$0.06
Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Niagen Bioscience, Inc. (NAGE) Q4 2024 Earnings Call Transcript
Confident tone
E-commerce and Tru Niagen channel
Niagen IV and Niagen Plus launch
Niagen ingredient business (food and pharmaceutical grade)
Revenue
$29.12M*
▲ 37.4% YoY Gross margin
62.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Niagen Bioscience, Inc. (NAGE) Q3 2024 Earnings Call Transcript
Confident tone
Niagen IV / Niagen Plus launch in clinics
E-commerce and TRU Niagen direct-to-consumer
Executive transition (new CFO)
Revenue
$25.58M
▲ 31.2% YoY Diluted EPS
$0.02
Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Niagen Bioscience, Inc. (NAGE) Q2 2024 Earnings Call
Revenue
$22.74M
▲ 11.9% YoY Diluted EPS
$0.00
Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Niagen Bioscience, Inc. (NAGE) Q1 2024 Earnings Call Transcript
Positive tone
Scientific Research & Pipeline
Retail Distribution Expansion
E-commerce & Digital Channels
Revenue
$22.15M
▼ 1.8% YoY Diluted EPS
$-0.01
Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Niagen Bioscience, Inc. (NAGE) Q4 2023 Earnings Call Transcript
Positive tone
Gross margin and mix
Q4 financial performance
Partnerships and partner brands
Revenue
$21.20M*
▲ 1% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Niagen Bioscience, Inc. (NAGE) Q3 2023 Earnings Call Transcript
Revenue
$19.50M
▲ 14.3% YoY Diluted EPS
$-0.01
Gross margin
61.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Niagen Bioscience, Inc. (NAGE) Q2 2023 Earnings Call Transcript
Revenue
$20.32M
▲ 21.5% YoY Diluted EPS
$-0.03
Gross margin
60.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Niagen Bioscience, Inc. (NAGE) Q1 2023 Earnings Call Transcript
Revenue
$22.56M
▲ 30.7% YoY Diluted EPS
$-0.03
Gross margin
59.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
Niagen Bioscience, Inc. (NAGE) Q4 2022 Earnings Call Transcript
Revenue
$21.00M*
▲ 18.2% YoY Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Niagen Bioscience, Inc. (NAGE) Q3 2022 Earnings Call Transcript
Revenue
$17.06M
▼ 1.4% YoY Diluted EPS
$-0.01
Gross margin
59.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Niagen Bioscience, Inc. (NAGE) Q2 2022 Earnings Call
Revenue
$16.73M
▼ 5.5% YoY Diluted EPS
$-0.09
Gross margin
60.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Niagen Bioscience, Inc. (NAGE) Q1 2022 Earnings Call Transcript
Revenue
$17.26M
▲ 17.5% YoY Diluted EPS
$-0.11
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-09
Niagen Bioscience, Inc. (NAGE) Q4 2021 Earnings Call Transcript
Revenue
$17.76M*
▲ 15% YoY Gross margin
61.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Niagen Bioscience, Inc. (NAGE) Q3 2021 Earnings Call Transcript
Revenue
$17.31M
▲ 22.1% YoY Diluted EPS
$-0.13
Gross margin
61.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Niagen Bioscience, Inc. (NAGE) Q2 2021 Earnings Call Transcript
Revenue
$17.70M
▲ 15.8% YoY Diluted EPS
$-0.08
Gross margin
61.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Niagen Bioscience, Inc. (NAGE) Q1 2021 Earnings Call Transcript
Revenue
$14.68M
▲ 2.4% YoY Diluted EPS
$-0.12
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Niagen Bioscience, Inc. (NAGE) Q4 2020 Earnings Call Transcript
Revenue
$15.45M*
▲ 18% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Niagen Bioscience, Inc. (NAGE) Q3 2020 Earnings Call Transcript
Revenue
$14.18M
▲ 17.6% YoY Diluted EPS
$-0.07
Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Niagen Bioscience, Inc. (NAGE) Q2 2020 Earnings Call Transcript
Revenue
$15.29M
▲ 37.7% YoY Diluted EPS
$-0.06
Gross margin
59.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Niagen Bioscience, Inc. (NAGE) Q1 2020 Earnings Call Transcript
Revenue
$14.35M
▲ 42.8% YoY Gross margin
57.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-10
Niagen Bioscience, Inc. (NAGE) Q4 2019 Earnings Call
Revenue
$13.09M*
▲ 44.4% YoY Gross margin
57.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 webcasts
Key facts
CIK
1386570
CUSIP
171077407
13F (30d)
128 filings
116 filers
Visit website
Investor relations